To be or not to bupropion: a drug-induced parkinsonism?
Objective: To draw attention to drug-induced parkinsonism. Background: Although the main causes of parkinsonism are degenerative, there are some reversible causes, including drug-induced parkinsonism. Method:…Epileptic seizures in patients with parkinsonism: experience of a tertiary centre
Objective: We aim to evaluate seizure frequency in patients with parkinsonism in a tertiary centre. Background: Observational studies suggest that the prevalence of epilepsy in…Clinical, imaging and genetic profile of patients with NBIA spectrum disorders
Objective: To describe the clinical, imaging and genetic profile of patients with suspected NBIA disorders Background: NBIA disorders are clinically, radiologically and genetically heterogenous group…The impact of Parkinson’s disease on multifactorial aspects of attention
Objective: (1) To characterize the differential effects of PD on the two attentional networks and (2) To examine the ability of attentional measurements differentiate between…sleep disturbance and wakefulness in parkinson’s disease
Objective: a complete study of sleep disorders and their adequate treatment Background: Sleep and wake disturbances are the second most common non-motor symptom of Parkinson's…Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations
Objective: To systematically examine the Columbia University LRRK2 brain bank for TDP-43 deposits Background: LRRK2 G2019S mutations have been associated with parkinsonism and a wide range of…Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
Objective: To investigate the association of plasma p-tau181 and NfL with cognitive performance and cognitive progression in PD patients. Background: Cognitive impairment (CI) is a…Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612
Objective: To describe the long-term experience of three individual patients receiving subcutaneous (SC) levodopa/carbidopa infusion with ND0612 in an open-label clinical safety study. Background: ND0612…A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage Parkinson’s disease: Rationale and study design
Objective: To describe the study design of a Phase 1b to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in individuals with…GRIN2D is a cause of autosomal dominant form of Parkinson’s disease
Objective: To identify novel genes involved in the familial form of Parkinson’s disease (PD) in the Indian population. Background: Most of the familial forms of…
- « Previous Page
- 1
- …
- 107
- 108
- 109
- 110
- 111
- …
- 153
- Next Page »